scholarly journals Two-Hour Postprandial Lipoprotein Particle Concentration Differs Between Lean and Obese Individuals

2019 ◽  
Vol 10 ◽  
Author(s):  
Ehsan Parvaresh Rizi ◽  
Sonia Baig ◽  
Tze Ping Loh ◽  
Sue-Anne Toh ◽  
Chin Meng Khoo ◽  
...  
Keyword(s):  
Particle Concentration ◽  
Lipoprotein Particle ◽  
Postprandial Lipoprotein

scholarly journals Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women

2017 ◽  
Vol 63 (4) ◽  
pp. 870-879 ◽  
Author(s):  
Patrick R Lawler ◽  
Akintunde O Akinkuolie ◽  
Paul M Ridker ◽  
Allan D Sniderman ◽  
Julie E Buring ◽  
...  
Keyword(s):  
Particle Concentration ◽  
Cox Proportional Hazards ◽  
Health Study ◽  
Linear Regression Models ◽  
Apo B ◽  
Healthy Women ◽  
Lipoprotein Particle ◽  
High Particle Concentration ◽  
High Particle ◽  
Chd Risk

Abstract BACKGROUND It is uncertain whether measurement of circulating total atherogenic lipoprotein particle cholesterol mass [non–HDL cholesterol (nonHDLc)] or particle concentration [apolipoprotein B (apo B) and LDL particle concentration (LDLp)] more accurately reflects risk of incident coronary heart disease (CHD). We evaluated CHD risk among women in whom these markers where discordant. METHODS Among 27533 initially healthy women in the Women's Health Study (NCT00000479), using residuals from linear regression models, we compared risk among women with higher or lower observed particle concentration relative to nonHDLc (highest and lowest residual quartiles, respectively) to individuals with agreement between markers (middle quartiles) using Cox proportional hazards models. RESULTS Although all 3 biomarkers were correlated (r ≥ 0.77), discordance occurred in up to 20.2% of women. Women with discordant high particle concentration were more likely to have metabolic syndrome (MetS) and diabetes (both P < 0.001). Over a median follow-up of 20.4 years, 1246 CHD events occurred (514725 person-years). Women with high particle concentration relative to nonHDLc had increased CHD risk: age-adjusted hazard ratio (95% CI) = 1.77 (1.56–2.00) for apo B and 1.70 (1.50–1.92) for LDLp. After adjustment for clinical risk factors including MetS, these risks attenuated to 1.22 (1.07–1.39) for apo B and 1.13 (0.99–1.29) for LDLp. Discordant low apo B or LDLp relative to nonHDLc was not associated with lower risk. CONCLUSIONS Discordance between atherogenic particle cholesterol mass and particle concentration occurs in a sizeable proportion of apparently healthy women and should be suspected clinically among women with cardiometabolic traits. In such women, direct measurement of lipoprotein particle concentration might better inform CHD risk assessment.

scholarly journals Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

2015 ◽  
Vol 9 (3) ◽  
pp. 377-383 ◽  
Author(s):  
Christie M. Ballantyne ◽  
Rene A. Braeckman ◽  
Harold E. Bays ◽  
John J. Kastelein ◽  
James D. Otvos ◽  
...  
Keyword(s):  
Particle Concentration ◽  
Icosapent Ethyl ◽  
Lipoprotein Particle

Abstract 012: Psoriasis is Associated With Atherogenic Lipoprotein Particle Concentration and Size Independent of Cardiometabolic Risk Factors

Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Ron C Li ◽  
Parasuram Krishnamoorthy ◽  
YiDing Yu ◽  
Jules Antigua ◽  
Anna Raper ◽  
...  
Keyword(s):  
Risk Factors ◽  
Particle Concentration ◽  
Cardiometabolic Risk ◽  
Traditional Risk Factor ◽  
Cardiometabolic Risk Factors ◽  
Cvd Risk Factors ◽  
Cvd Risk ◽  
Atherogenic Lipoprotein ◽  
Lipoprotein Particle ◽  
Increased Risk

Introduction: Psoriasis is a chronic inflammatory skin disease associated with increased risk of cardiovascular disease (CVD). We have previously shown that psoriasis is associated with atherogenic lipoprotein particle concentration and size. However, it is unknown whether this association is independent of traditional CVD risk factors or insulin resistance (IR). Methods: We prospectively enrolled a consecutive sample of patients with psoriasis (n=122) and compared cardiometabolic risk factors with an asymptomatic sample without psoriasis from our practice (n=129). Fasting lipids, insulin, glucose were measured by standard assays, and lipoprotein concentration and size were measured by nuclear magnetic resonance (NMR) (LipoScience, North Carolina). HOMA-IR, an estimation of IR, was calculated by standard methods. Multivariable linear regression for adjusted models was performed using STATA12 software. Results: LDL-C and HDL-C were lower in psoriasis compared to controls [106.9 mg/dL (90-132.5) vs 128 (110.2-145.6), p<0.01 and 43 mg/dL (36-58) vs 50 (42-62), p<0.01] with no difference in triglycerides. However, NMR showed an atherogenic profile in psoriasis similar to that observed in diabetes, with significant increase in LDL [1210.5 (1002-1498) vs 1115 (935-1291), p=0.03] particle concentration with a concomitant decrease in LDL size [20.6 (20.3-21.1) vs 21.3 (20.6-21.1), p<0.001] even after adjusting for obesity, tobacco use, hypertension, lipids, and HOMA-IR (p=0.001). An increase in VLDL particle concentration was also seen before [61.9 (38.3-95.3) vs 53.4 (30.4-84.5), p=0.05] and after adjusting for cardiometabolic risk factors (p=0.018). Conclusions: Despite normal lipids, we demonstrate a more atherogenic lipoprotein profile by NMR in psoriasis compared to healthy controls after adjustment for CVD risk factors and IR. These findings suggest that traditional risk factor analysis and lipid testing may not ideally capture the increased CVD risk observed in psoriasis.

Sign in / Sign up

Export Citation Format

Share Document